Dear Members,
Your Directors have the pleasure in presenting the Twenty Fourth Board's Report of Medi
Assist Healthcare Services Limited (the 'Company' or 'MAHS') together with the Audited
Financial Statements (Consolidated and Standalone) for the financial year ended March
31,2024.
1) OVERVIEW OF FINANCIAL PERFORMANCE
(Amount in ' millions)
Particulars |
Standalone |
Consolidated |
|
FY 2024 |
FY 2023 |
FY 2024 |
FY 2023 |
Revenue from operations |
1,084.23 |
637.88 |
6,347.25 |
5,049.34 |
Other income |
221.69 |
217.13 |
183.23 |
140.21 |
Total revenue |
1,305.92 |
855.01 |
6,530.48 |
5,189.55 |
Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) |
377.71 |
32.82 |
1,333.05 |
1,193.46 |
Finance Cost |
1.64 |
3.32 |
31.64 |
29.89 |
Depreciation and amortization |
115.24 |
57.02 |
430.77 |
267.69 |
Profit before tax (excluding exceptional item) |
482.52 |
189.61 |
1,053.87 |
1,036.09 |
Tax Expenses |
60.52 |
23.68 |
130.92 |
283.01 |
Profit after tax (excluding exceptional item and from continuing operations) |
212.00 |
165.93 |
922.95 |
753.08 |
Other comprehensive income/(expense) for the year, net of income tax |
13.02 |
(61.78) |
13.98 |
(58.30) |
Total comprehensive income for the year, net of tax (excluding exceptional item) |
207.50 |
104.15 |
915.80 |
682.12 |
Performance Highlights
During the financialyear 2023-2024, your Company along with its group companies, has
delivered strong growth in revenue from operations of 25.70 % on a year-on-year basis.
The Company on a standalone basis, clocked a total revenue of ' 1,305.92
millions resulting in Earnings Before Interest, Tax, Depreciation and Amortization
(EBITDA) of ' 377.71 millions and Profit Before Tax (excluding exceptional item) of
' 482.52 millions, an increase of 154.48% on a year-on-year basis.
The consolidated total revenue of the Company for the financial year 2023-24 was '
6,530.48 millions as compared to ' 5,189.55 millions in the previous year, an
increase of 25.84% on a year-on-year basis.
The detailed operational performance of the Company has been comprehensively discussed
in the Management Discussion and Analysis Report, which forms part of this Annual Report.
2) INITIAL PUBLIC OFFERING & LISTING OF EQUITY SHARES OF THE COMPANY
During the year under review, your Company completed an Initial Public Offering ('IPO')
in the form of an offer for sale of 2,80,28,168 equity shares of face value of '
5/- each aggregating to ' 11,715.77 millions.
The issue opened on January 15, 2024 and closed on January 17, 2024. The issue was led
by Book Running Lead Managers viz., Axis Capital Limited, IIFL Securities
Limited, Nuvama Wealth Management Limited and SBI Capital Markets Limited.
Pursuant to IPO, the equity shares of the Company are listed on the National Stock
Exchange of India Limited and BSE Limited effective January 23, 2024.
Your Directors would like to thank the Merchant Bankers, legal counsels and other
stakeholders for helping the Company achieve the successfullPO and listing. Your Directors
would also like to thank the regulators, Securities and Exchange Board of India and
Registrar of Companies for enabling the Company to take its equity story to the public
market.
Last but not least, your Directors extend their heartfelt gratitude to the shareholders
for investing in the IPO and reposing their continuous trust and faith in the Company and
its management.
3) DIVIDEND
The Board of Directors have recommended a final dividend of ' 4/- per equity
share of face value of ' 5/- each for the financial year ended March 31, 2024,
which is subject to approval of the Members in the ensuing Annual General Meeting of the
Company.
In terms of Regulation 43A of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 ('SEBI Listing Regulations'), the Dividend Distribution
Policy is available on the Company's website and can be accessed at
https://mediassist.in/assets/pdf/policy/ dividend-distribution-policy.pdf
4) TRANSFER TO GENERAL RESERVES
During the year under review, the Company has transferred ' 193.62 millions to
retained earnings.
Further, the closing balance of retained earnings as at March 31, 2024 after all
appropriation and adjustments was ' 659.63 millions.
5) SUBSIDIARIES/JOINT VENTURES AND ASSOCIATES
During the year under review, the following corporate actions were undertaken:
a) Acquisition of Raksha Health Insurance TPA Private Limited
To accelerate and further strengthen Company's presence in group and retail schemes,
the group acquired Raksha Health Insurance TPA Private Limited ('Raksha') effective August
25, 2023.
This acquisition was undertaken by Medi Assist Insurance TPA Private Limited
('MAITPA'), a wholly owned subsidiary of the Company, which acquired 100% of equity shares
of Raksha.
b) Amalgamation of Medvantage Insurance TPA Private Limited
The Regional Director vide its order dated February 5, 2024 approved the scheme
amalgamation of Medvantage Insurance TPA Private Limited ('Medvantage') with Medi Assist
Insurance TPA Private Limited, a wholly owned subsidiary of the Company. The said
amalgamation is effective from February 13, 2024.
The amalgamation is in line with the plan submitted to the IRDAI and allows for
synergies in customer servicing and operations.
As at March 31, 2024, the Company has 4 direct subsidiaries and 4 indirect
subsidiaries, as under:
a) Medi Assist Insurance TPA Private Limited, India
b) International Healthcare Management Services Private Limited, India
c) Mayfair Consultancy Services India Private Limited, India
d) Mayfair We Care Limited, UK
e) Raksha Health Insurance TPA Private Limited, India
f) Mayfair Group Holding Subcontinent Limited, UK
g) Mayfair We Care PTE. Ltd, Singapore
h) Mayfair We Care Philippines Limited, Philippines
There has been no material change in the nature of business of the subsidiaries. There
are no associates or joint venture companies within the meaning of Section 2(6) of the
Companies Act, 2013 (the 'Act').
6) ACCOUNTS OF SUBSIDIARIES
The consolidated financial statements of the Company for the financial year 2023-2024
are prepared in compliance with the applicable provisions of the Act including Indian
Accounting Standards specified under Section 133 of the Act.
Audited financial statements of each of the subsidiary companies is available on the
website of the Company and can be accessed at https://mediassist.in/investor-
relations/
Further, pursuant to the provisions of Section 129(3) of the Act, a statement
containing salient features of the financial statements of the Company's subsidiaries as
required in Form AOC 1 is appended as Annexure-1 to this Report.
7) MATERIAL SUBSIDIARIES
The Board of Directors of the Company has adopted a Policy for determining material
subsidiaries in line with the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015. The Policy is available at Company's website at
https://mediassist.in/assets/pdf/policy/policy- on-material-subsidiaries.pdf
For the financial year 2023-24, Medi Assist Insurance TPA Private Limited and Raksha
Health Insurance TPA Private Limited are categorized as material subsidiary(s) of the
Company as per the thresholds laid down under the SEBI Listing Regulations.
8) SHARE CAPITAL Authorized Share Capital
The Authorized Share Capital of the Company is ' 45,35,00,000/- divided into
9,07,00,000 equity shares of face value of ' 5/- each.
Issued, Subscribed and Paid-Up Share Capital
During the financialyear 2023-2024, the paid up share capital of the Company has
increased from ' 34,42,96,060/- divided into 6,88,59,212 equity shares of face
value of ' 5/- each to ' 35,10,46,230/- divided into 7,02,09,246 equity
shares of face value of ' 5/- each.
There has been an increase in the paid-up share capital of the Company during the
financial year on account of allotment of 13,50,034 equity shares consequent to exercise
of stock options by employees under 'Employee Stock Option Scheme 2013' of the Company.
9) BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL ('KMP') OF THE COMPANY
The composition of the Board of Directors is in due compliance with the Companies Act,
2013 and SEBI Listing Regulations. There was no change in the Directors or Key Managerial
Personnel of the Company during the year under review.
As at March 31, 2024, the Board of the Company comprises of 9 Directors of which 2 are
Executive Directors, 2 are Nominee Directors and 5 are Non-Executive Independent
Directors, details of which are provided below:
Name |
Designation |
Executive Directors |
|
1. Dr. Vikram Jit Singh Chhatwal |
Chairman & Whole-Time Director (KMP) |
2. Mr. Satish V N Gidugu |
Whole-Time Director & Chief Executive Officer (KMP) |
Non-Executive Directors |
|
3. Mr. Anil Kumar Chanana |
Non-Executive Independent Director |
4. Mr. Gopalan Srinivasan |
Non-Executive Independent Director |
5. Dr. Ritu Niraj Anand |
Non-Executive Independent Director |
6. Ms. Himani Atul Kapadia |
Non-Executive Independent Director |
7. Mr. Ananda Mukerji |
Non-Executive Independent Director |
8. Mr. Vishal Vijay Gupta |
Non-Executive Nominee Director |
9. Mr. Gaurav Sharma |
Non-Executive Nominee Director |
Other KMPs |
|
10. Mr. Mathew George* |
Chief Financial Officer |
11. Ms. Simmi Singh Bisht |
Chief Compliance Officer & Company Secretary |
*Mr. Mathew George, Chief Financial Officer resigned with effect from closing business
hours of May 16, 2024.
Further, the Board at its meeting held on May 15, 2024 appointed Mr. Sandeep Daga as
Chief Financial Officer of the Company with effect from May 17, 2024.
Retirement by Rotation & Re-appointment
A proposal for re-appointment of Mr. Vishal Vijay Gupta (DIN: 01913013) retiring
director, as Non-Executive Nominee Director of the Company shall be placed before Members
of the Company at the ensuing AGM.
Your Directors recommend his re-appointment on the Board of the Company. Disclosures
pertaining to Director being re-appointed as required under the SEBI Listing Regulations
and Secretarial Standard on General Meetings issued by the Institute of Company
Secretaries of India is provided in the explanatory statement to the Notice convening the
AGM of the Company for reference of the Shareholders.
During the year under review, the Non-Executive/ Independent Directors of the Company
had no pecuniary relationship or transactions with the Company, other than sitting fees,
commission and reimbursement of expenses, if any.
None of the Directors of the Company are disqualified under Section 164(1) or Section
164(2) of the Act.
10) BOARD MEETINGS
The Board of Directors met 11 times during the said financial year on the following
dates:
a) June 23, 2023
b) July 7, 2023
c) July 21,2023
d) August 2, 2023
e) August 25, 2023
f) December 15, 2023
g) January 3, 2024
h) January 9, 2024
i) January 17, 2024
j) February 13, 2024
k) March 27, 2024
Gap between two Board meetings during the year under review did not exceed one hundred
and twenty days. Requisite quorum was present for all the meetings.
The details of attendance of the Directors in the meeting are provided in the Corporate
Governance Report, which forms part of this Annual Report.
11) COMMITTEES OF THE BOARD
The Board has constituted committees to focus on specific areas and make informed
decisions within the authority delegated to each of the Committees. The Company has
following Committees as on March 31, 2024:
a) Audit Committee
b) Nomination and Remuneration Committee
c) Stakeholders Relationship Committee
d) Risk Management Committee
e) Corporate Social Responsibility Committee
Details of meetings of the Board Committees held during the financialyear 2023-2024
along with information relating to attendance of each director/committee member is
provided in the Corporate Governance Report, which forms part of this Annual Report.
12) INDEPENDENT DIRECTORS' MEETING
The meeting of Independent Directors was held on February 9, 2024, without the
attendance of NonIndependent Directors and members of the management. The Independent
Directors reviewed the performance of Non-Independent Directors, the Committees and the
Board as a whole, along with the performance of the Chairman of the Company, taking into
account the views of Executive Directors and Non-Executive Directors and assessed the
quality, quantity and timeliness of flow of information between the management and the
Board that is necessary for the Board to effectively and reasonably perform their duties.
13) ANNUAL PERFORMANCE EVALUATION OF THE BOARD
The Board has adopted a formal mechanism for evaluating its own performance and the
performance of its Committees and individual Directors, including the Chairman of the
Board.
The results of evaluation showed a high level of commitment and engagement of the
Board, its various committees and senior leadership. The recommendations arising from the
evaluation process were discussed at the Independent Directors meeting held on February 9,
2024.
For the year ended March 31, 2024, evaluation forms were circulated to the Board
Members which included the evaluation of the Board as a whole, Board Committees and Peer
evaluation of the Directors. Each Director completed the evaluation form and shared their
feedback. The feedback scores as wellas qualitative comments were shared with the
Chairperson of Nomination and Remuneration Committee. The outcome and action points were
discussed by the Nomination and Remuneration Committee at its meeting held on February 13,
2024. The overall feedback of the evaluation process was positive.
14) POLICY ON DIRECTORS APPOINTMENT AND REMUNERATION
Pursuant to Section 178(3) of the Act and Regulation 19 & Schedule II Part D of the
SEBI Listing Regulations, the Nomination and Remuneration Committee of the Company has
formulated the criteria for identification and Board nomination of the suitable candidates
as well as the policy on remuneration for Directors, KMP and other employees of the
Company. The Committee, while evaluating potential candidates for Board membership,
considers a variety of personal attributes, including experience, intellect, foresight,
judgment and transparency and matches these with the requirements set out by the Board.
The Nomination & Remuneration Policy of the Company provides the framework for
remunerating the members of the Board, Key Managerial Personnel and other employees of the
Company. This Policy is guided by the principles and objectives enumerated in Section
178(4) of the Act and Regulation 19 read along with Schedule II Part D of the SEBI Listing
Regulations.
The Remuneration Policy for Directors, Key Managerial Personnel and Senior Management
Personnel inter-alia, provides for criteria and qualifications for appointment of
Director, Key Managerial Personnel and Senior Management, Board Diversity, remuneration to
Directors, Key Managerial Personnel, etc. is available on the website of the Company and
can be accessed at https://mediassist.
in/assets/pdf/policy/nomination-and-remuneration- policy.pdf
15) DECLARATION BY INDEPENDENT DIRECTORS
In accordance with Section 149(7) of the Act and Regulation 25(8) of the SEBI Listing
Regulations, each Independent Director has confirmed to the Company that they continue to
meet the criteria of independence as laid down in Section 149(6) of the Act and Regulation
16(1)(b) of SEBI Listing Regulations.
In opinion of the Board, Independent Directors of the Company possess necessary
expertise, integrity, experience and proficiency in their respective fields. Further, all
Independent Directors have confirmed that they have registered with the data bank of
Independent Directors maintained by; and are either exempt or have completed the online
proficiency self-assessment test conducted by; the Indian Institute of Corporate Affairs
in accordance with the provisions of Section 150 of the Act.
16) AUDITORS AND AUDIT REPORTS Statutory Auditors
At the 22nd Annual General Meeting of the Company held on September 28,
2022, M/s. MSKA & Associates, Chartered Accountants (FRN - 105047W) were appointed as
the statutory auditors of the Company for a period of five years, from the conclusion of
the 22nd AGM till the conclusion of the 27th Annual General Meeting
of the Company to be held in the year 2027-2028.
The Auditors' Report provided by M/s. MSKA & Associates for the financial year
ended March 31, 2024, is enclosed along with the financial statements in the Annual
Report. The Auditors' Report does not contain any qualifications, observations or adverse
remarks.
Internal Auditors
M/s. PricewaterhouseCoopers Services LLP, Chartered Accountants were the Internal
Auditors of the Company for the financial 2023-2024.
Secretarial Auditors
M/s. BMP & Co. LLP, a firm of Practicing Company Secretaries has conducted the
Secretarial Audit of the Company for the financial year 2023-24. The Secretarial Audit
Report is appended as Annexure-2 to this report. The report does not contain any
qualification, reservation or adverse remark.
Further, in compliance to Regulation 24A of SEBI Listing Regulations, the material
unlisted subsidiaries of the Company i.e., Medi Assist Insurance TPA Private Limited and
Raksha Health Insurance TPA Private Limited have undertaken the secretarial audit for the
financial year 2023-2024. The Secretarialaudit reports of the said subsidiaries are
appended as Annexure-2A and Annexure-2B to this report. The report(s) do not
contain any qualification, reservation or adverse remarks.
Cost Auditors
Maintenance of cost records as specified by the Central Government under Section 148(1)
of the Act is not applicable to the Company.
17) INTERNAL FINANCIAL CONTROLS
The Company's internal financial controlsystems are commensurate with its size and
nature and the complexity of its operations and such internal financial controls are
adequate and are operating effectively. The Company has adopted policies and procedures
for ensuring orderly and efficient conduct of the business. These controls have been
designed to provide reasonable assurance regarding recording and providing reliable
financial and operational information, adherence to the Company's policies, safeguarding
of assets from unauthorized use and prevention and detection of frauds and errors, the
accuracy and completeness of the accounting records, and the timely preparation of
reliable financial disclosures.
During the year under review, such controls were tested and no material weaknesses in
their design or operations were observed.
18) CORPORATE GOVERNANCE REPORT
Your Company provides utmost importance to the best Governance practices and is
designed to act in the best interest of its stakeholders.
The Corporate Governance Report along with the Auditor's Certificate for the year under
review, as stipulated under SEBI Listing Regulations forms part of the Annual Report.
19) MANAGEMENT DISCUSSION AND ANALYSIS REPORT
The Management's Discussion and Analysis Report for the year under review, as
stipulated under the SEBI Listing Regulations forms part of the Annual Report.
20) BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT
As per the SEBI Listing Regulations, Business Responsibility and Sustainability Report
of the Company for the financial year 2023-2024 forms a part of this Annual Report.
21) EMPLOYEE STOCK OPTION SCHEME
The Employee Stock Option Scheme of the Company titled 'Employee Stock Option Scheme
2013' ('ESOP Scheme') was implemented in the financial year 2013-2014.
During the year under review, the Company has obtained in-principle approvals from the
Stock Exchanges in relation to the said scheme for allotment of equity shares against the
vested stock options.
A statement giving detailed information on stock options granted to employees under the
ESOP Scheme as required under Section 62 of the Act and Regulation 14 of SEBI (Share Based
Employee Benefits and Sweat Equity) Regulations, 2021 is available on Company's website
and can be accessed at https://mediassist.in/assets/pdf/
investor-relations/mahs/esop/esop-annexure-fy-23-24.pdf
22) PARTICULARS OF EMPLOYEES
Disclosures pertaining to remuneration and other details as required under Section
197(12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of
ManagerialPersonnel) Rules, 2014 are provided in the prescribed format and appended as Annexure-3
to this Report.
As per the provisions of Section 197(12) of the Act read with Rule 5(2) and 5(3) of the
Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement
containing names of top ten employees in terms of remuneration drawn and the particulars
of employees forms part of this report. However, in terms of the first proviso to Section
136(1) of the Act, Annual Report excluding the aforesaid information, is being sent to
Shareholders of the Company and others entitled thereto.
Any shareholder interested in obtaining a copy thereof, may write to the Chief
Compliance Officer & Company Secretary of the Company at investor.relations@
mediassist.in
23) CORPORATE SOCIAL RESPONSIBILITY
The Company undertakes one or more activities which fall within the provisions of
Section 135 and Schedule VII of the Act.
Medi Assists' CSR initiatives help address socio-economic challenges in the realms of
Healthcare, Education, Skill development and Sustainable livelihoods and Support employee
engagement in CSR activities.
The disclosures as required under Section 135 of the Act read with Rule 8(1) of the
Companies (Corporate Social Responsibility Policy) Rules, 2014 along with committee
constitution details is appended as Annexure-4 to this Report.
24) PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS
The Company has not provided any loans or guarantee under Section 186 of the Act.
Details of Investments covered under the provisions of Section 186 of the Act, are given
in Note no. 7(a) to the standalone financial statements in the Annual Report.
25) CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES
During the financial year 2023-2024, all the transactions with related parties were
entered into at arms' length basis and in the ordinary course of business. As required
under Section 188(1) of the Act, disclosure in Form AOC-2 is appended as Annexure-5 to
this Report.
The Company's policy on dealing with Related Parties is available on the Company's
website and can be accessed at https://mediassist.in/assets/pdf/policy/
policy-on-related-party-transactions.pdf
26) RISK MANAGEMENT
The Company has a risk management framework for identification and management of risks.
In line with the SEBI Listing Regulations, the Company has constituted a Risk
Management Committee ('RMC') comprising members of the Board of Directors. Terms of
reference of the Committee and composition thereof including details of meetings held
during the financial year 2023-2024 forms part of the Corporate Governance Report, which
forms part of this Annual Report.
Additional details relating to Risk Management are provided in the Management
Discussion and Analysis Report forming part of this Report. Further, Risk Management
Policy of the Company can be accessed at https://mediassist.in/assets/pdf/policy/risk-management-
policy.pdf
27) CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS &
OUTGO
(A) Conservation of Energy
(i) The steps taken or impact on conservation of energy:
Your Company is an environmentally responsible organization. While we are not in an
energy intensive industry and hence do not require any special measures to be taken, the
Company is focused on positive ecological impact as a responsible member of the society.
Adequate measures are taken to reduce and restrict usage of nonperishable and harmful
materials and several initiatives are in the process of being implemented towards
conserving energy, recycling, water preservation in the office premises as well as
switching off air conditioners, lights, computers, etc. when not in use.
(ii) The steps taken by the Company for utilizing alternate sources of energy include
proper waste management and recycling initiatives:
For the Company, the predominant wastage is in the form of paper. The Company follows
proper disposal processes including post shredding the paper, waste is given to an
external agency for recycling.
(iii) Capital investment on energy conservation equipment: Nil
(B) Technology Absorption
Medi Assist has embarked on a significant modernization initiative, transforming 80% of
its technology stack. By transitioning from traditional hypervisors to open-source
technology and highly scalable container orchestration for microservices, the Company has
achieved substantial energy savings and reduced totalcost of ownership. 5 This
strategic move has also enabled efficient resource pooling, further enhancing operational
efficiency.
To amplify these benefits, Medi Assist has deployed realtime dashboards across various
departments. These \ dashboards provide immediate visibility into critical
performance indicators, empowering stakeholders to proactively monitor operations,
identify trends, and address potential issues before they escalate. This data-driven
approach fosters collaboration, streamlines communication, and promotes a culture of
accountability throughout the organization.
In a move to further differentiate itself in the IPMI market,
Medi Assist has chosen to develop its platform in-house.
This collaborative approach allows the business team to work closely with product,
engineering, and data science teams, ensuring alignment between business goals and
technological capabilities. Moreover, inhouse development enables Medi Assist to preserve
its intellectual property, providing a distinct competitive advantage and positioning the
Company at the forefront : of healthcare technology innovation. ;
(C) Foreign Exchange Earnings and Outgo
The particulars of Foreign Exchange and Outgo are as mentioned hereunder:
(Amount in ' millions)
Particulars |
2023-2024 |
2022-2023 |
Foreign exchange earnings |
4.54 |
0.28 |
Foreign exchange outgo |
2.45 |
8.77 |
28) PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE
As per the requirements under the Sexual Harassment of Women at Workplace (Prevention,
Prohibition & Redressal) Act, 2013 ('POSH Act') and Rules made thereunder, the Company
has constituted Internal Complaints Committee ('ICC'). To build awareness in this area,
the Company has been conducting necessary training in the organization on an ongoing
basis.
While maintaining the highest governance norms, the Company has appointed the following
members of ICC as below:
a) A Presiding officer or Chairperson who is a woman employed at a senior level at the
workplace from amongst the employees.
b) The Company has appointed an external independent person committed to this cause and
who has the requisite experience in handling such matters, as other members of ICC.
c) Not less than two members from amongst employees are committed to the cause of
women; their safety and have experience in social work and have legal knowledge.
The following is a summary from the Annual return filed for the period ended March
31,2024 under POSH Act:
Particulars |
Number |
a. Number of complaints pending at the beginning of the year |
NIL |
b. Number of complaints received during the year |
NIL |
c. Number of complaints disposed of during the year |
NIL |
d. Number of cases pending at the end of the year |
NIL |
e. Number of cases resolved beyond 90 days |
NIL |
29) AWARDS AND ACCOLADES
During the financial year 2023-2024, the group has won the following awards and
accolades for business and operational excellence:
a) Best Use of Predictive Analysis for Fraud Detection, 2024 - Awarded by Quantic India
at the Data Analytics & AI Show 2024.
b) TPA of the Year, March 7, 2024 - Awarded by Synnex Group at the India Insurance
Summit.
30) OTHER DISCLOSURES
a) Nature of Business
There has been no change in the nature of business of the Company during the year under
review.
b) Remuneration details as per Schedule V of the Act
In terms of Schedule V Part II (Remuneration) of the Companies Act, 2013, the
remuneration details of the Directors appointed under Chapter XII of the Companies Act,
2013 forms part of the Corporate Governance Report which forms part of this Annual Report.
c) Details relating to Deposits covered under Chapter V of the Act
During the year under review, the Company has neither accepted nor renewed any deposits
from the public within the meaning of Section 73 of the Act and the Companies (Acceptance
of Deposits) Rules, 2014. Hence, the requirement for furnishing of details relating to
deposits covered under Chapter V of the Act or the details of deposits which are not in
compliance with Chapter V of the Act is not applicable.
d) Loans from Directors or Director's Relatives
During the financial year 2023-2024, the Company has not borrowed any amount(s) from
Directors and/or their relatives.
e) Disclosure with respect to Demat Suspense/Unclaimed Suspense Account
The Company does not maintain any Demat Suspense/ Unclaimed Suspense Account and
accordingly the disclosure pertaining as required under Schedule V Para F of SEBI (Listing
Obligations and Disclosure Requirement) Regulations, 2015 is not applicable to the Company
for the period under review.
f) Vigil Mechanism/Whistle Blower Policy
The Company has a robust vigil mechanism in place, which is in conformity with the
provisions of the Act and SEBI Listing Regulations.
The said policy provides appropriate avenues to the directors, employees and
stakeholders of the Company to make protected disclosures in relation to matters
concerning the Company.
This mechanism also provides for adequate safeguards against victimization of
Director(s)/employee(s) who avail of the mechanism and also provides for direct access to
the Chairman of the Audit Committee in exceptional cases. The details of the Whistle
Blower Policy and the Committee which oversees the compliance are explained in detail in
the Corporate Governance Report.
During the financial year 2023-2024, the Company has not received any protected
disclosure.
g) Reporting of Fraud
No frauds were reported by the Auditors as specified under Section 143 of the Act for
the financial year ended March 31, 2024.
h) Annual Return of the Company
Pursuant to Section 92(3) of the Act, the Annual Return in Form MGT-7 has been uploaded
on the website of the Company and can be accessed at https://mediassist.in/
investor-relations/
i) Significant and material orders passed by Regulators or Courts
There were no significant or material orders passed by the regulators or courts or
tribunals impacting the going concern status and Company's operations in future.
j) Material changes and commitments, if any
There were no material changes and commitments affecting the financial position of the
Company which occurred between the end of the financial year to which this financial
statement relates and the date of this report.
k) Secretarial Standards
The Company has complied with all applicable mandatory secretarial standards issued by
the Institute of Company Secretaries of India.
l) Transfer of Unclaimed Dividend to Investor Education and Protection Fund
There has been no unclaimed dividend and hence the provisions of Section 125(2) of the
Act do not apply.
m) Insolvency and Bankruptcy Code, 2016
During the year, the Company has not made any application under the Insolvency and
Bankruptcy Code, 2016 ('IBC Code'). Further, there is no Corporate Insolvency Resolution
Process initiated under the IBC Code.
n) Details of one time settlement while taking loan from the banks or financial
institutions along with the reasons thereof
During the year, there was no one-time settlement done with the Banks or Financial
Institutions. Therefore, the requirement to disclose details of difference between amounts
of valuation done at the time of one-time settlement and the valuation done, while taking
loan from Banks or Financial Institutions along with reasons thereof, is not applicable.
o) Details of utilization of funds raised through preferential allotment or qualified
institutional placement as specified under Regulation 32(4) and 32(7A) of the SEBI Listing
Regulations During the financial year under review, the Company has not made any
preferential allotment or qualified institutionalplacement. However, the Company has made
Initial Public Offer ('IPO') in the form of Offer for Sale and hence the provisions with
respect to Regulation 32 of SEBI Listing Regulations is not applicable to the Company for
the said IPO.
p) Disclosure under Section 43(a)(ii) of the Act
The Company has not issued any shares with differential rights and hence no information
as per provisions of Section 43(a)(ii) of the Act is furnished.
q) Disclosure under Section 54(1)(d) of the Act
The Company has not issued any sweat equity shares during the year under review and
hence no information as per provisions of Section 54(1)(d) of the Act is furnished.
r) Disclosure under Section 67(3) of the Act
During the year under review, there were no instances of non-exercising of voting
rights in respect of shares purchased directly by employees under a scheme pursuant to
Section 67(3) of the Act read with Rule 16(4) of Companies (Share Capital and Debentures)
Rules, 2014.
31) DIRECTORS' RESPONSIBILITY STATEMENT
Pursuant to the requirement under Section 134(5) of the Act with respect to the
Directors' Responsibility Statement, the Board of Directors of your Company state that:
a) in the preparation of the annual financial statements, the applicable accounting
standards have been followed along with proper explanation relating to 61 material
departures;
b) the Directors have selected such accounting policies and applied them consistently
and made judgments co and estimates that are reasonable and prudent so as to give a true
and fair view of the state of affairs of the Company at the end of the financial year and
of the profit of the Company for that period;
c) the Directors have taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of the Companies Act, 2013 for
safeguarding the assets of the Company and for preventing and detecting fraud and other
irregularities;
d) the annual financial statements have been prepared on a going concern basis;
e) proper internal financial controls were laid down and that the internal financial
controls are adequate and operating effectively;
f) the Directors have devised proper systems to ensure compliance with the provisions
of all applicable laws and such systems are adequate and operating effectively.
32) ACKNOWLEDGEMENT
Your Directors wish to place on record their immense appreciation for the continued
support and cooperation of all the stakeholders.
The Directors also wish to thank our employee-partners for their unwavering support and
contribution to the successful operations of the Company and look forward to their
continued support.
For and on behalf of the Board of Directors |
|
Dr. Vikram Jit Singh Chhatwal |
Satish V N Gidugu |
Chairman and Whole-Time Director |
Whole-Time Director & Chief Executive Officer |
DIN: 01606329 |
DIN:06643677 |
Date: May 15, 2024 |
|
Place: Bengaluru |
|